GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » European Biotech Acquisition Corp (NAS:EBACU) » Definitions » 5-Year Yield-on-Cost %

European Biotech Acquisition (European Biotech Acquisition) 5-Year Yield-on-Cost % : 0.00 (As of May. 19, 2024)


View and export this data going back to 2021. Start your Free Trial

What is European Biotech Acquisition 5-Year Yield-on-Cost %?

European Biotech Acquisition's yield on cost for the quarter that ended in Dec. 2022 was 0.00.


The historical rank and industry rank for European Biotech Acquisition's 5-Year Yield-on-Cost % or its related term are showing as below:



EBACU's 5-Year Yield-on-Cost % is not ranked *
in the Diversified Financial Services industry.
Industry Median: 3.68
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of European Biotech Acquisition's 5-Year Yield-on-Cost %

For the Shell Companies subindustry, European Biotech Acquisition's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


European Biotech Acquisition's 5-Year Yield-on-Cost % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, European Biotech Acquisition's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where European Biotech Acquisition's 5-Year Yield-on-Cost % falls into.



European Biotech Acquisition 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of European Biotech Acquisition is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

European Biotech Acquisition  (NAS:EBACU) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


European Biotech Acquisition 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of European Biotech Acquisition's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


European Biotech Acquisition (European Biotech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
EPFL Innovation Park Building, Lausanne, CHE, 1015
European Biotech Acquisition Corp is a blank check company.
Executives
Mohammad Sohail Fazeli director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Martijn Kleijwegt director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Volkert H. Doeksen director RIOUWSTRAAT 10, THE HAGVE P7 2585HA
Fernandez De Araoz Eduardo Bravo officer: Chief Executive Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Koen Sintnicolaas officer: Chief Financial Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Sponsor Ebac B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Van De Stolpe Onno director JOHANNES VERMEERPLEIN 9, AMSTERDAM, P7 1071 DV
Marcus Antonius Wegter director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Management Group B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV

European Biotech Acquisition (European Biotech Acquisition) Headlines